Understanding how PD-L1 signaling affects immune responses in the skin
PD-L1 reverse signaling in dermal DCs promotes DC migration and skin immunity to cutaneous pathogens
['FUNDING_R01'] · UNIVERSITY OF COLORADO DENVER · NIH-10898824
This study is looking at how a specific signal in immune cells called dendritic cells helps them move and work better during skin infections, which could lead to new ways to boost our skin's ability to fight off germs.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF COLORADO DENVER (nih funded) |
| Locations | 1 site (Aurora, UNITED STATES) |
| Trial ID | NIH-10898824 on ClinicalTrials.gov |
What this research studies
This research investigates how PD-L1 reverse signaling in dendritic cells influences their movement and function during skin infections. By examining the mechanisms that control dendritic cell migration from the skin to lymph nodes, the study aims to uncover how this signaling affects T cell activation and immune responses. The researchers will explore the role of PD-L1 in responding to signals from pathogens and how it regulates the immune system's ability to fight infections. This work could lead to new insights into improving skin immunity and responses to cutaneous pathogens.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals with skin infections or autoimmune diseases affecting the skin.
Not a fit: Patients with non-cutaneous infections or those without immune system involvement may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could enhance our understanding of skin immunity and lead to better treatments for skin infections and autoimmune conditions.
How similar studies have performed: Other research has shown promising results in understanding immune signaling pathways, suggesting that this approach could yield valuable insights.
Where this research is happening
Aurora, UNITED STATES
- UNIVERSITY OF COLORADO DENVER — Aurora, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: TAMBURINI, BETH ANN — UNIVERSITY OF COLORADO DENVER
- Study coordinator: TAMBURINI, BETH ANN
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.